Toshihisa Ishikawa obtained the Ph.D. degree from the Graduate School of Science, Hokkaido University, Japan, in March 1982. In the same year, he received the scholarship of the Deutscher Akademischer Austauschdienst and moved to West Germany. From 1982 till 1987, he was a Postdoctoral Fellow at the Institute of Physiological Chemistry, Medical School of University Düsseldorf, in Germany. In April 1987, he came back to Japan and was appointed to Assistant Biochemist at the Department of Biochemistry, Medical School of Osaka University, Japan. In 1989, he became the Project Leader of the Department of Tumor Biochemistry at German Cancer Research Institute in Heidelberg. In 1991, Dr. Ishikawa left Germany for the USA and was appointed to an Assistant Professor at the Department of Experimental Pediatrics, University of Texas M.D. Anderson Cancer Center in Huston, Tex, USA. In addition, he had an adjunct appointment of Assistant Professor at the Graduate School of Health Science Center, University of Texas. In 1993, he received a research award from the International Life Sciences Institute (Washington, DC). In December 1995, he was appointed to the Senior Scientist and Manager at the Department of Medicinal Biology in the Central Research of Pfizer Pharmaceuticals, Inc. and thereafter became the Director of the Department of Research Technology Development at the Japanese Headquarters of Pfizer Pharmaceuticals, Inc. in Tokyo, in 1999. From 2000 till May 2009, Dr. Ishikawa was a Professor at the Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Japan. He is presently a Professor and directing the Pharmacogemics Project at the Omics Science Center in RIKEN Yokohama Institute. Dr. Ishikawa is a Member of the International Nomenclature Committee for Human ABC Transporter Genes. Most recently, he was one of the Steering Committee Members to organize the FDA Critical Path Transporter Workshop held in Bethesda, Md, USA, in October 2 and 3, 2008.
Biography Updated on 7 November 2009